Flamel Technologies

Since the acquisition of Éclat, we have implemented a balanced business model allowing Flamel to commercialize niche branded (Bloxiverz®® and Vazculep®) and generic pharmaceutical products in the U.S. and other countries as appropriate, and blend novel, high-value internally developed products with our drug delivery and capabilities. Flamel’s new model allows us now to select, develop, seek approval for, and commercialize niche branded products mainly in the U.S. and most of the opportunities are self-funded. By adopting this revised strategy, the Company makes itself less dependent on the often changing strategies of partners in the future. Nevertheless, Flamel is still exploring development, supply and licensing opportunities for either its drug delivery platforms or its proprietary products with carefully selected third parties, but, unlike our historical operations, will not be dependent completely on those partnerships to create revenue and profit opportunities.
Type
Public
HQ
Vénissieux, FR
Founded
1990
Size (employees)
109 (est)
Website
flamel.com
Flamel Technologies was founded in 1990 and is headquartered in Vénissieux, FR

Flamel Technologies Office Locations

Flamel Technologies has an office in Vénissieux

Flamel Technologies Data and Metrics

Flamel Technologies Financial Metrics

$, USD

Net income (FY, 2015)

40.7 m

EBIT (FY, 2015)

71.4 m

Market capitalization (18-Nov-2016)

432.2 m

Closing share price (18-Nov-2016)

10.8

Cash (31-Dec-2015)

65.1 m
Flamel Technologies's current market capitalization is $432.2 m.
$, USDFY, 2015

R&D expense

25.6 m

General and administrative expense

21.7 m

Operating expense total

47.3 m

EBIT

71.4 m

Interest expense

(1.4 m)

Pre tax profit

78.4 m

Income tax expense

37.7 m

Net Income

40.7 m
$, USDFY, 2015

Cash

65.1 m

Current Assets

166.3 m

PP&E

2.6 m

Goodwill

18.5 m

Total Assets

215 m

Accounts Payable

612 k

Current Liabilities

48.8 m

Additional Paid-in Capital

364 m

Retained Earnings

(279.8 m)

Total Equity

67.9 m

Financial Leverage

3.2 x
$, USDFY, 2015

Net Income

40.7 m

Depreciation and Amortization

13.1 m

Cash From Operating Activities

84.3 m

Purchases of PP&E

(1.6 m)

Cash From Investing Activities

(31.7 m)

Cash From Financing Activities

(23.8 m)

Interest Paid

4.7 m
Y, 2015

Financial Leverage

3.2 x

Flamel Technologies Company Life and Culture

You may also be interested in